Albion Financial Group Lineage Cell Therapeutics, Inc. Transaction History
Albion Financial Group
- $1.42 Billion
- Q3 2024
A detailed history of Albion Financial Group transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Albion Financial Group holds 3,043 shares of LCTX stock, worth $1,582. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,043
Previous 3,043
-0.0%
Holding current value
$1,582
Previous $3,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding LCTX
# of Institutions
121Shares Held
94.2MCall Options Held
63.8KPut Options Held
1K-
Broadwood Capital Inc New York, NY41.7MShares$21.7 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$4.97 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.6MShares$4.47 Million0.0% of portfolio
-
Defender Capital, Llc.5MShares$2.6 Million1.58% of portfolio
-
Logos Global Management LP San Francisco, CA5MShares$2.6 Million0.6% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $88.3M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...